6th Annual Digital Immuno-Oncology Innovation Forum

About the forum
With the rapid spread of the coronavirus pandemic this is a timely review of the industry response to the crisis. Topics covered during the 6th Annual Immuno-Oncology Innovation Forum (IOIF) include development strategies and clinical trials, the challenge of finance and investment for biotechs. With the cancellation of major industry conferences, this digital event allows the Immune-oncology (IO) community to be updated on the most recent developments and to network with colleagues across the world using our online video meeting platform. We are keen to support our community and, with the virtual conference, can offer all the benefits attendees would usually expect.
The Sachs IOIF brings together leaders from cancer research institutes, patient advocacy groups, early- and late-stage investors, pharma and biotech companies. The programme will cover licensing and investment opportunities in the immuno-oncology field.
The virtual IOIF conference will consist of:
|
As the first major digital event considering COVID-19, Sachs will expand marketing activities and provide free access to view panel discussions and presentations for all interested participants. This will allow Sachs to increase audience size and enhance exposure for participating companies.
Premium online meeting system access will be provided free for qualified institutional (buy/sell- side), private equity and venture investors and also for partnering & licensing executives representing big pharma companies. The number of passes is limited and priority will be given given to regular participants. However, Sachs has discretion to reject applications. The system will allow you to have a secure audio/video call, as well as an option to present slides using the screen sharing function. Meetings will last for 30 minutes. Others may choose to purchase basic, advanced or premium online meeting system access with an option for a pre-recorded five minute showcase presentation.
Plenary and therapeutic sessions on 26 May include: | Plenary and therapeutic sessions on 27 May include: |
|
|
Presenting opportunities
Presenting at the forum offers excellent opportunities to showcase your company to some of the leading global investors and corporates. It will offer you the chance to communicate your capital-raising plans or simply help you find the right partner for your business. Presenting companies from Europe and the US will benefit from specially designed panels and keynote addresses from leading industry figures and give you access to some of the leading analysts and investors from Europe and beyond. This year, we aim to expand the audience and once again provide opportunities for executive-level networking, deal-making and strategic partnering.
About Sachs Associates
Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global medtech industry. This, together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.
Summary
Event: 6th Annual Digital Immuno-Oncology Innovation Forum
Date: 26–27 May 2020
Location: Online
Hosted by: Sachs Associates
About: With the rapid spread of the coronavirus pandemic, this is a timely review of the industry response to the crisis. Topics covered during the 6th Annual immuno-oncology Innovation Forum (IOIF) include development strategies and clinical trials, the challenge of finance and investment for biotechs. With the cancellation of the major industry conferences, this digital event allows the immune-oncology (IO) community to be updated on the most recent developments and to network with colleagues across the world using our online video meeting platform. We are keen to support our community and, with the virtual conference, can offer all the benefits attendees would usually expect.
For more information or to register your interest, contact the Sachs team on SachsTeam@sachsforum.com.